SCHEMBL27132597

SCHEMBL27132597

CCCc1ccc2cnn(C)c2c1NS(=O)(=O)c1cnn(-c2ccnc(C(F)(F)F)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 2/20 0.35
▸ GRIN1 Q05586 2/20 0.35
▸ GRIN2B Q13224 2/20 0.35
▸ CYP2D6 P10635 1/20 0.33
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ OXTR P30559 1/20 0.32
▸ AVPR1A P37288 1/20 0.32
▸ SLC40A1 Q9NP59 1/20 0.32
▸ DDX3X O00571 1/20 0.31
▸ SUCNR1 Q9BXA5 1/20 0.31
▸ AR P10275 1/20 0.31
▸ CHRM4 P08173 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30847769 1.00 RXRA (0.35) RXRAGRIN1GRIN2BCYP2D6PSEN1
SCHEMBL30848041 0.94 RXRA (0.38) RXRAGRIN1GRIN2BCYP2D6PSEN1
SCHEMBL27132346 0.94 RXRA (0.38) RXRAGRIN1GRIN2BCYP2D6PSEN1
SCHEMBL30848113 0.88 RXRA (0.33) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL27132350 0.88 RXRA (0.33) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL27132783 0.87 RXRA (0.36) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL30848042 0.87 RXRA (0.36) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL30847861 0.86 RXRA (0.37) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL27132406 0.86 RXRA (0.37) RXRAGRIN1GRIN2BOXTRAVPR1A
SCHEMBL30848073 0.86 RXRA (0.38) RXRAGRIN1GRIN2BCYP2D6PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 RXRA 3175/4885GRIN1 2434/4885GRIN2B 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback